GlassScriptPhysician profile
Andrew T Bridge
NPI 1174780837
$3,353.52
in general payments reported to CMS, 2019-2025
28 companies · $514 in 2025
The $514 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $173 · 2021: $131 · 2022: $92.70 · 2023: $1,098 · 2024: $448 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,225 · Food and Beverage: $782 · Education: $54.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,225.00 |
| Food and Beverage | $781.86 |
| Education | $54.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $1,225.00 | 2023-2024 | |
| Janssen Biotech, INC. | $689.92 | 2019-2025 | Tremfya |
| Abbvie INC. | $279.93 | 2019-2023 | Rinvoq |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.18 | 2019 | |
| Lilly USA, LLC | $123.88 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $113.09 | 2019-2020 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $100.00 | 2021 | |
| Pfizer INC. | $86.72 | 2019-2024 | |
| Incyte Corporation | $80.30 | 2025 | Opzelura |
| Mayne Pharma Commercial LLC | $58.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.57 | 2019-2021 | |
| Abbott Laboratories | $43.14 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $40.38 | 2019-2020 | |
| Dermira, INC. | $39.65 | 2019 | |
| Chiesi USA, INC. | $39.00 | 2024 | Filsuvez |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.39 | 2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $26.82 | 2019-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Corcept Therapeutics | $23.67 | 2024 | Korlym |
| Epi Health, LLC | $23.53 | 2019 | |
| Janssen Scientific Affairs, LLC | $21.65 | 2019 | |
| Sanofi Pasteur INC. | $20.56 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $19.01 | 2019 | |
| Exact Sciences Corporation | $16.63 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $14.93 | 2019 | |
| Almirall LLC | $14.20 | 2020 | |
| Vyne Pharmaceuticals INC. | $12.99 | 2020 | |
| Journey Medical Corporation | $3.87 | 2019 | |
| Prugen, INC. Pharmaceuticals | $3.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.